Pfizer Announces Positive Phase 3 Study Results for XELJANZ ® (tofacitinib) in Ankylosing Spondylitis (AS)
Biospace,
Nov. 6, 2020 11:45 UTC Late-breaking data to be presented at ACR Convergence: the American College of Rheumatology/Association…
Nov. 6, 2020 11:45 UTC Late-breaking data to be presented at ACR Convergence: the American College of Rheumatology/Association…
Pfizer Inc. (NYSE: PFE) announced today positive results from a Phase 3 investigational study evaluating the safety and…
Pfizer Inc. (NYSE: PFE) announced today positive results from a Phase 3 investigational study evaluating the safety and…
Nov. 6, 2020 11:45 UTC Late-breaking data to be presented at ACR Convergence: the American College of Rheumatology/Association…